Previous 10 | Next 10 |
FT MYERS, FL / ACCESSWIRE / May 27, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that senior management will be participating virtually in multiple upcoming institutional i...
FT. MYERS, FL / ACCESSSWIRE / May 10, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Douglas VanOort, Executive Chairman, Mark Mallon, Chief Executive Officer, and Kathr...
The following slide deck was published by NeoGenomics, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: NeoGenomics, Inc. 2021 Q1 - Results - Earnings Call Presentation
NeoGenomics, Inc. (NEO) Q1 2021 Earnings Conference Call May 5, 2021 08:30 AM ET Company Participants Doug VanOort - Chairman Mark Mallon - Chief Executive Officer Kathryn McKenzie - Chief Financial Officer George Cardoza - President, Pharma Services Division Bill Bonello - President, Informa...
Image source: The Motley Fool. Neogenomics Inc (NASDAQ: NEO) Q1 2021 Earnings Call May 5, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Neogenomics Inc (NEO) Q1 2021 Earnings Call Transcript
NeoGenomics (NEO): Q1 Non-GAAP EPS of -$0.04 misses by $0.05; GAAP EPS of -$0.19 misses by $0.14.Revenue of $115.53M (+9.0% Y/Y) beats by $3.36M.Clinical Services revenue increased 4% to $96 millionPharma Services revenue increased 46% to $19 millionCompleted the acquisition of Trapelo Health...
First-Quarter 2021 Results and Highlights: Consolidated revenue increased 9% to $116 million Clinical Services revenue increased 4% to $96 million Pharma Services revenue increased 46% to $19 million Completed the acquisition of Trapelo Health in April FORT MYERS...
Establishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing market NeoGenomics exercises option struck in May 2020 to purchase remaining equity stake for $390 million Completes $200 million strategic financing with leading oncology-focused special...
NeoGenomics (NASDAQ:NEO) is scheduled to announce Q1 earnings results on Wednesday, May 5th, before market open.The consensus EPS Estimate is $0.01 and the consensus Revenue Estimate is $112.17M (+5.8% Y/Y).Over the last 2 years, NEO has beaten EPS estimates 88% of the time and has beate...
SGT Program will provide KRAS G12C testing to eligible patients at no cost, regardless of insurance type. FT. MYERS, FL / ACCESSWIRE / April 19, 2021 / NeoGenomics, Inc. (NASDAQ:NEO) , a leading provider of cancer-focused genetic testing services and global oncology contract research ser...
News, Short Squeeze, Breakout and More Instantly...
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its second quarter 2024 financial results after the close of the U.S. financial markets on Monday, July 29, 2024. Company management will host a webcast and conference call at 4:30 ...
2024-06-23 10:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that Fort Myers’ Mayor, Kevin Anderson, will be dedicating June as NeoGenomics’ Commitment to Cancer Month to honor cancer survivors and those currently living with cancer. Headquartered in...